IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across ...
It looks like an ordinary contact lens, but when exposed to near-infrared light, it emits the ultraviolet light used for ...
Immatics (IMTX) announced updated Phase 1a dose escalation data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated ...
Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma December 11, 2025 9:00 ...
Smithsonian Magazine on MSN
A Deadly Pathogen Decimated Sunflower Sea Stars. Look Inside the Lab Working to Bring Them Back by Freezing and Thawing Their Larvae
For the first time, scientists have cryopreserved and revived the larvae of a sea star species. The breakthrough, made with ...
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse's GigaLab to generate data for its ...
International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors ...
A soft, edible electrode made from alginate and polydopamine detects glucose under intestinal conditions, opening a path toward swallowable sensors for diabetes monitoring.
S&P 500 may hit 7,800 by 2026, fueled by tech and AI growth. Discover top defense AI stocks to watch amid rising US, NATO ...
Intensity Therapeutics, Inc. ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent ...
By Kisean Joseph [email protected] The Ministry of Education, Sports and Creative Industries will host its ...
Detailed price information for Niagen Bioscience Inc (NAGE-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback